Simulation: 'Pymaceuticals, Inc.', a new pharmaceutical company that specializes in anti-cancer medications, began screening for potential treatments for squamous cell carcinoma (SCC), a commonly occurring form of skin cancer.
Given access to the complete data from a simulated animal study. In this study, 249 mice who were identified with SCC tumors received treatment with a range of drug regimens. Over the course of 45 days, tumor development was observed and measured. The purpose of this study was to compare the performance of Pymaceuticals’ drug of interest, Capomulin, against the other treatment regimens.
Tasked with generating tables and figures needed for technical report of the clinical study. Provided a top-level summary of the study results.